Press Releases InnoCan Pharma Corporation Deutsche Boerse AG

Equities

IP4

CA45783P1027

Market Closed - Deutsche Boerse AG Other stock markets 12:55:25 07/06/2024 BST			5-day change	1st Jan Change
0.1945 ^EUR	+6.28%		+0.78%	-0.36%

05-27	InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-27	Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million	05-27	AQ
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	05-21	AQ
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	05-09	AQ
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	04-22	AQ
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M	04-01	AQ
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.	03-25	AQ
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million	03-15	AQ
Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study	03-05	AQ
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits	02-26	AQ
Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024	02-20	AQ
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights	02-13	AQ
Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST	02-05	AQ
Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration	12-12	AQ
Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues Compared to Q3, 2022	11-29	AQ
Innocan Pharma Announces Promising LPT-CBD Safety Indications -Implications from a prolong use in animals	11-03	AQ
Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and global CBD research	23/10/23	AQ
Innocan Pharma Announces Closing of Second and Final Tranche of Financing	20/10/23	AQ
Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update	12/10/23	AQ
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million	21/09/23	GL
Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board	15/09/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases InnoCan Pharma Corporation Deutsche Boerse AG

Equities

IP4

CA45783P1027

Press Releases

Filters